reMYND identifies novel target and small molecules with potential to halt and reverse disease progression in Huntington’s disease through oral administration
29-08-2022

Leuven Belgium, 31 August 2022: reMYND NV, a clinical stage company tackling neurodegeneration, today announces positive preclinical results from its drug discovery program ReS18-H to treat Huntington’s Disease (HD), a rare monogenic disease that causes the progressive breakdown of nerve cells in the brain by neurotoxic mutant huntingtin, leading to movement, cognitive and psychiatric dysfunction.

Read more
reMYND’s novel Alzheimer program reports excellent brain exposure and safety profile in Phase 1; transitioning into Phase 2a
03-05-2022

Leuven Belgium, 03 May 2022: reMYND NV, a clinical stage company tackling neurodegeneration, today announces that its lead Alzheimer program ReS19-T has successfully completed its Phase 1 study. Topline data has demonstrated excellent brain exposure and strong safety profile. These results support the next phase of clinical development, a Phase 2a proof-of-mechanism study slated for initiation soon.

Read more
reMYND and the US NINDS Epilepsy Therapy Screening Program (ETSP) begin collaboration on epilepsy program
04-11-2021

Leuven Belgium, 4 November 2021: reMYND NV, a clinical stage company developing innovative treatments for Alzheimer’s, diabetes, epilepsy and other diseases caused by cellular dysfunction, today announces the acceptance of ReS3-T, the Company’s lead epilepsy drug candidate, into the US NIH’s National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP). The ReS3-T program is the result of a collaboration with KU Leuven’s Centre for Drug Design and Discovery (CD3).

Read more
reMYND’s ReS19-T program, managing calcium homeostasis for Alzheimer’s, has moved to MAD phase after demonstrating strong safety in SAD phase
21-10-2021

Leuven Belgium, 21 October 2021: reMYND NV, a clinical stage company, is pleased to announce that it has initiated the multiple-ascending-dose (MAD) phase of its Alzheimer’s program after observing no compound-related ReS19-T adverse events so far in the 58 healthy volunteers in the single-ascending dose (SAD) phase.

Read more
reMYND announces Clinical Advisory Board to support development of Alzheimer’s programme
19-05-2021

Leuven Belgium, 20 May 2021: reMYND NV, a clinical stage company developing innovative treatments for Alzheimer’s, diabetes and other diseases caused by cellular dysfunction, is pleased to announce the Clinical Advisory Board (CAB) which will support the Company as it progresses its programme in Alzheimer’s disease (“Alzheimer’s”).

Read more
reMYND commences first-in-human trial of ReS19-T Alzheimer’s program
02-12-2020

-  RES-19T represents a novel approach to treat Alzheimer’s at the root of the disease and restore cognition

-  Board and Senior Leadership team strengthened; appointment of Staph Leavenworth Bakali as Chair and Hermann Russ as Chief Medical Officer

 

Read more
Interreg. project "Memories" update
01-07-2020

An intermediate update on the progress of identifying differently expressed microRNA in Alzheimer's Disease.

Read more
Approved project ‘Memories’: early diagnostics of Alzheimer’s disease (AD)
08-03-2018

Interreg granted a positive ruling on the project ‘Memories’ mid-December. reMYND will team up with the consortium partners ToxGenSolutions, Icometrix, KU Leuven, Maastricht University and UAntwerpen to support AD research aimed at a sustainable, inclusive growth among Flanders and South-Netherlands. The entire project will receive almost € 800.000 in funding from Interreg. The province of Flemish Brabant will support the project with an additional sum of nearly € 150.000.

Read more
reMYND receives grants from Flanders and Europe to advance break-through treatments in Epilepsy and Alzheimer’s
14-03-2017
reMYND NV today announced that it has received two grants from Flanders and Europe to advance break-through treatments in Epilepsy and Alzheimer’s respectively.
Read more
reMYND to present on Biotechdag
19-10-2015
reMYND will be presenting on the research towards the treatment of Alheimers and diabetes worldwide.
Read more